ViralEd, LLC - PrEP Guidelines 2022

PrEP Guidelines 2022

About the Program

Target Audience
Learning Objectives
Faculty
Joint Accreditation Statement
Credit Designation
Disclosure of Conflicts of Interest
Method of Participation and Request for Credit
Disclosure of Unlabeled Use
Disclaimer

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

Describe the need for PrEP and the types of PrEP that are available
Discuss the roles of clinicians and pharmacists in providing PrEP
Apply effective PrEP based on current and updated CDC guidelines
Identify barriers to PrEP and provide counseling to patients about PrEP

Release Date: March 30, 2022

Expiration Date: March 30, 2023

Media: Internet

Estimated time to complete each Module: 30 minutes

Back to Top

Faculty

Paul Djuricich, PharmD, AAHIV Clinical Pharmacist Specialist Univeristy of Chicago Medicine Chicago, Illinois	Richard A. Elion, MD Associate Professor of Clinical Medicine George Washington University Medical Center Washington, DC
Ian Frank, MD Professor of Medicine Director, Clinical Therapeutics Program Penn Center for AIDS Research Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania	Renslow Sherer, MD Professor of Medicine Section of Infectious Diseases and Global Health University of Chicago Chicago, Illinois

Back to Top

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Back to Top

Credit Designation

Physician Continuing Medical Education and Continuing Pharmacy Education

Case 1 (Initial Therapy After Acquiring HIV – Is It Too Late for PrEP?):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Postgraduate Institute for Medicine designates this continuing medical education activity for .50 contact hour(s)(0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-22-114-H01-P
Type of Activity: Knowledge

Case 2 (Pregnancy, Side effects and Insurance Issues):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 3 (PrEP for a Transgender Woman):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRAPRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 4 (PrEP 2+1+1: MSM/IDU with an STI):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 5 (Long-Acting PrEP for Cis-Gender Women):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all thier financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineleigible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the content of this CME activity:

Paul Djuricich, PharmD

No real or apparent conflicts to disclose

Richard Elion, MD

Consultant/Advisory Board: Merck, Gilead, ViiV
Speakers Bureau/Honoraria for non-CME: Gilead, ViiV
Other financial or material support (Expert Wigness): Gilead

Ian Frank, MD

Consultant/Advisory Board: Gilead, GSK, Johnson & Johnson, ViiV
Grant/Research Support: Johnson & Johnson, Moderna, Sanofi Genzyme, Pfizer

Renslow Sherer, MD

Grant/Research Support: Gilead

The PIM planners and others have nothing to disclose. The ViralEd, Inc. planners and others have nothing to disclose

Back to Top

Method of Participation and Request for Credit

1) Go to http://www.cmeuniversity.com/

2) Login or Create a New Account (will take less than 1 minute)
a) If you receive a message when creating a new account that "the email you entered is already in use", please click the Forgot my Username or Password link to have your Username and Password sent to you via email
b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 16956 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) Complete the Post-test with a passing score of 75% or better
7) Complete the online Evaluation
8) Receive an immediate CE Certificate to download and/or print for your files
9) For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

For CME Accreditation Questions, please click HERE

VE logo 300px

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs

Back to Top

ViralEd, LLC

https://www.viraled.com/modules/info/prep_guidelines_2022.html